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Abstract: Esophageal cancer with airway invasion with or without
fistula presents a challenging therapeutic dilemma with no standard
therapy. Recent studies in Japan have focused on the use of defin-
itive chemoradiotherapy. However, this approach is associated with
significant treatment-related morbidity and mortality. We present a
case report of a patient with thoracic esophageal squamous cell
carcinoma with bronchial invasion who was treated to a clinical
complete response with induction chemotherapy followed by con-
solidation with concurrent chemoradiotherapy. The patient also
underwent restaging with a positron emission tomography scan after
induction chemotherapy. Such a staged approach may reduce the
morbidity of upfront radiation. The use of an interim positron
emission tomography scan may also identify early treatment failure.
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Esophageal cancer with airway invasion with or withoutfistula presents a challenging therapeutic dilemma with no
standard therapy. Left untreated, patients with airway fistulas
have median survivals of only 1 to 6 weeks.1
Recent studies from Japan have focused on the use of
combined chemoradiotherapy to treat patients with T4 tumors
with or without fistulas.2,3 While these studies have demon-
strated long-term survival in a minority of patients, they have
also been associated with the worsening or development of
new fistulas as well as treatment-related deaths in a signifi-
cant proportion of patients.
Here, we present a case report of a patient with a T4
esophageal squamous cell carcinoma (SCC) with invasion of
the bronchus who experienced a clinical complete response to
induction chemotherapy and consolidative chemoradiotherapy.
CASE REPORT
The patient is a 70-year-old man who presented in April
2007 with increasing dysphagia for solid foods and a 10 lb
weight loss. Endoscopy established a tumor in the mid esoph-
agus at 25 to 31 cm from the incisors, with biopsy positive for
an invasive poorly differentiated SCC.
A position emission tomography/computed axial to-
mography (PET/CT) scan revealed intense uptake in the
primary tumor (standard uptake value 13.6) without evidence
of metastatic disease. A CT scan of the chest/abdomen
demonstrated a paraesophageal fluid- and gas-containing
structure that was concerning for a small fistula. There was
also evidence of locoregional lymphadenopathy.
An endoscopic ultrasound initially staged the tumor as
an uT3N1 lesion. However, slight mucosal irregularity of the
left mainstem bronchus was seen on subsequent flexible
bronchoscopy. Biopsy returned positive for a poorly differ-
entiated carcinoma that was morphologically similar to the
esophageal primary. As such, this was staged as a T4 esoph-
ageal cancer.
The patient received induction chemotherapy with
weekly cisplatin 25 mg/m2 and irinotecan 50 mg/m2 on a
2-week on/1-week off schedule. After two cycles, the patient
had experienced complete resolution of dysphagia. A repeat
PET/CT scan indicated a significant decrease in standard
uptake value to 5.7 of the primary tumor. CT scan of the
chest/abdomen also demonstrated resolution of the prior para-
esophageal fluid collection and improvement of esophageal
thickening.
After an additional two cycles of chemotherapy, a
repeat bronchoscopy revealed a complete response in the
bronchus, with negative cytologic analysis of bronchial wash-
ings. Endoscopy showed significant downsizing of the pri-
mary tumor.
The patient then received consolidative radiation with
25 daily fractions of 1.8 Gy over 51⁄2 weeks to a total dose of
50.4 Gy with concurrent cisplatin/irinotecan at the above
doses and schedule. He tolerated all therapy without signifi-
cant toxicity.
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At the completion of therapy, he was followed expect-
antly. Endoscopy 3 months after completion of therapy con-
firmed a clinical complete response, with negative esophageal
brushings. Repeat CT scans of the chest/abdomen obtained 2
and 5 months after completion of therapy also detected no
evidence of recurrence. The patient is now without evidence
of disease 12 months after his initial diagnosis and 6 months
after completion of therapy. Representative CT images are
presented in Figure 1.
DISCUSSION
In the United States, the incidence of esophageal cancer
with airway invasion is fairly uncommon. In a series from the
Washington, D.C. Veterans’ Affairs hospital from 1985 to
1998, 20% of patients with established esophageal cancer had
airway involvement, with 9.4% having fistulous connec-
tions.4 Most (88%) of these patients had SCC, consistent with
the location of these tumors in the cervical and proximal
esophagus. As the incidence of the SCC histology has
steadily decreased in the general population so that the
adenocarcinoma histology now predominates, the incidence
of airway invasion with or without fistulas also seems to have
decreased.
The treatment of esophageal cancer with airway inva-
sion with or without fistula continues to present difficult
management decisions. Primary surgical resection is gener-
ally considered inadvisable because of the substantial treat-
ment-related mortality and morbidity. In a series of 28 pa-
tients with known airway invasion without fistulas who
underwent surgical exploration with or without esophagec-
tomy, the operative mortality was 17%.5
Other approaches have included palliative treatments,
such as the placement of endoesophageal stents to relieve
malignant dysphagia or to occlude a fistula or single-modality
radiation therapy.1
The seminal Radiation Therapy Oncology Group 85-01
trial established the superiority of chemoradiotherapy over
radiotherapy alone for the nonsurgical management of locally
advanced esophageal cancer.6 As such, there has also been
significant interest in the use of chemoradiotherapy either as
preoperative or definitive therapy for T4 esophageal tu-
mors—despite potential concerns for creating or worsening
fistulas.1,4
In a phase I/II evaluation, Nishimura et al.3 treated
28 patients with esophageal squamous cell cancers with
airway invasion with or without fistulas. Patients received
protracted infusion 5-fluorouracil and cisplatin, along with
split-dose radiation to a total dose of 60 Gy over 30
fractions. This study reported an encouraging 2-year sur-
vival rate of 27% for the patients with stage III (T4NM0)
disease. However, this was at the expense of significant
toxicity, including the development or worsening of fistu-
las in 18% of patients and treatment-related deaths in 7%
of patients.
In our case report, the patient received induction
therapy with weekly cisplatin/irinotecan followed by che-
moradiotherapy with the same regimen and achieved a
clinical complete response. Induction chemotherapy in the
setting of T4 tumors has several theoretical benefits. As the
use of radiation therapy has been associated with concerns
about worsening fistulas, chemotherapy alone may effec-
tively downstage the primary tumor but may be associated
with a lower rate of fistula formation. Chemotherapy is
also highly effective in relieving malignant dysphagia in
up to 70 to 80% of patients7 and may obviate the need for
placement of an esophageal stent or enteral feeding tube.
In addition, the use of an interim PET scan after
induction chemotherapy offers several potential advan-
tages. A patient who develops metastatic disease despite
effective systemic chemotherapy may be spared the toxic-
ity of radiation therapy. At the same time, there are
anecdotal data to suggest that patients who experience
local progression after induction chemotherapy may be
successfully salvaged with alternative chemotherapy dur-
ing concurrent radiation.8
Finally, the benefit of surgery after chemoradiother-
apy is unclear, particularly in the setting of a baseline T4
tumor. Two recent randomized trials (which included pa-
tients with T4 tumors) have not demonstrated a survival
benefit for surgery after chemoradiotherapy in patients
with esophageal SCC,9,10 justifying the approach of ex-
pectant observation in this patient with a clinical complete
response.
To our knowledge, there has been no prior descrip-
tion of the use of induction chemotherapy followed by
concurrent chemoradiotherapy to treat patients with T4
esophageal tumors. Such an approach represents a staged
and potentially effective treatment paradigm. Initial che-
motherapy may be associated with a lower risk of fistula
formation than chemoradiotherapy and may also down-
stage the tumor and improve dysphagia. The use of an
interim PET scan after induction chemotherapy may iden-
tify early treatment failure in the form of overt metastatic
disease or local progression that can permit a modulation
in therapy. Patients who achieve a clinical complete re-
sponse can be followed expectantly while salvage surgery
remains an option for those with locally persistent disease.
FIGURE 1. Computed tomography
images (A) at baseline, (B) after two
cycles of induction chemotherapy
and (C) 5 months after completion
of combined modality therapy. Ar-
rows indicate esophageal thickening.
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